glp-1 news Prescriptions Quadruple Since 2021 Alongside Decline In Obesity On The Pen GLP-1 News
Description
D.KoyfmanA.LongB
Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp
As there is no meaningful expression of GLP-1 receptors on hepatocytes, the major effect of GLP-1 agonists on MASH is likely to be indirect and may be related to a reduction in calorie intake, body weight and insulin resistance, all of which would lead to reduced liver lipid accumulation and hepatic inflammation 7,8
The OASIS 4 trial, organized by drugmaker Novo Nordisk, showed that after taking the pill for 64 weeks, participants lost an average of 13.6 percent of their body weight
51: 22632270 [DOI] [PubMed] [Google Scholar] 113.Thomsen C, Rasmussen O, Lousen T, et al
Additionally, higher endogenous calcitonin levels in individuals with obesity has been reported (90)
